Product Description
Oliceridine is a novel selective µ-receptor G-protein pathway modulator. It has the property of activating G-protein signaling while causing low beta-arrestin recruitment to the µ-receptor. Intravenous oliceridine showed statistically superior analgesia than placebo in patients with moderate or severe pain after surgery, with a favorable safety and tolerability profile regarding respiratory and gastrointestinal adverse effects, compared with morphine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33423508/)
Mechanisms of Action: OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: Trevena
Company Location:
Company CEO: Carrie L. Bourdow
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- PDUFA date set for August 7, 2020 for IV oliceridine resubmission; milestone progress reported by Trevena, Inc.
Highest Development Phases
Phase 4: Other|Chronic Pain|Pain, Postoperative|Acute Pain|Respiratory Insufficiency|Burns Unspecified|Depressive Disorder|Dizziness|Abdominal Pain|Morphine Dependence|Bursitis|Dehydration|Pneumoperitoneum|Bunion|Constipation|Anesthesia Related|Hypotension|Tobacco Use Disorder
Phase 3: Acute Pain
Phase 2: Acute Pain|Pain, Postoperative
Phase 1: Pain Unspecified|Acute Pain|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500109984 |
ChiCTR2500109984 | N/A |
Not yet recruiting |
Urethral Stricture |
2030-09-30 |
|||
ChiCTR2500108926 |
ChiCTR2500108926 | N/A |
Not yet recruiting |
Urethral Stricture |
2029-02-01 |
|||
ChiCTR2500106005 |
ChiCTR2500106005 | N/A |
Not yet recruiting |
Other |
2028-07-01 |
|||
ChiCTR2500114192 |
ChiCTR2500114192 | N/A |
Not yet recruiting |
Depressive Disorder |
2028-09-01 |
|||
ChiCTR2500115473 |
ChiCTR2500115473 | N/A |
Not yet recruiting |
Pain, Postoperative |
2028-06-30 |
|||
ChiCTR2500111411 |
ChiCTR2500111411 | N/A |
Not yet recruiting |
Unknown |
2028-03-31 |
|||
ChiCTR2500096971 |
ChiCTR2500096971 | N/A |
Not yet recruiting |
Pain Unspecified |
2028-01-31 |
|||
ChiCTR2500096869 |
ChiCTR2500096869 | N/A |
Not yet recruiting |
Depressive Disorder |
2028-01-31 |
|||
ChiCTR2400088652 |
ChiCTR2400088652 | N/A |
Not yet recruiting |
Anesthesia Related|Depressive Disorder |
2027-12-31 |
|||
ChiCTR2500110643 |
ChiCTR2500110643 | N/A |
Not yet recruiting |
Hypotension|Bradycardia |
2027-12-31 |
|||
ChiCTR2500115441 |
ChiCTR2500115441 | N/A |
Not yet recruiting |
Tuberculosis, Spinal|Delirium|Pain, Postoperative |
2027-12-31 |
|||
ChiCTR2500114767 |
ChiCTR2500114767 | N/A |
Not yet recruiting |
Unknown |
2027-12-31 |
|||
ChiCTR2500115661 |
ChiCTR2500115661 | N/A |
Not yet recruiting |
Chronic Pain |
2027-12-31 |
|||
ChiCTR2500110297 |
ChiCTR2500110297 | N/A |
Not yet recruiting |
Other |
2027-12-31 |
|||
ChiCTR2400094706 |
ChiCTR2400094706 | N/A |
Not yet recruiting |
Osteoarthritis |
2027-12-01 |
|||
ChiCTR2500111214 |
ChiCTR2500111214 | N/A |
Not yet recruiting |
Acute Pain|Pain, Postoperative |
2027-11-30 |
|||
ChiCTR2500110374 |
ChiCTR2500110374 | N/A |
Not yet recruiting |
Cesarean Section |
2027-11-01 |
|||
ChiCTR2500111369 |
ChiCTR2500111369 | N/A |
Not yet recruiting |
Colorectal Cancer |
2027-11-01 |
|||
ChiCTR2500101324 |
ChiCTR2500101324 | N/A |
Not yet recruiting |
Depressive Disorder |
2027-10-31 |
|||
ChiCTR2500110159 |
ChiCTR2500110159 | N/A |
Not yet recruiting |
Pain, Postoperative |
2027-10-15 |
|||
ChiCTR2500103999 |
ChiCTR2500103999 | N/A |
Not yet recruiting |
Unknown |
2027-10-01 |
|||
ChiCTR2500114668 |
ChiCTR2500114668 | N/A |
Not yet recruiting |
Depressive Disorder|Cognitive Dysfunction|Delirium |
2027-09-30 |
|||
ChiCTR2600116391 |
ChiCTR2600116391 | N/A |
Not yet recruiting |
Pain, Postoperative |
2027-09-30 |
|||
ChiCTR2500108562 |
ChiCTR2500108562 | N/A |
Not yet recruiting |
Delirium |
2027-08-31 |
|||
ChiCTR2500113535 |
ChiCTR2500113535 | N/A |
Not yet recruiting |
Pain, Postoperative |
2027-08-31 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/04/2024 |
News Article |
Trevena Announces Receipt of Nasdaq Delisting Notification |
|
08/08/2024 |
News Article |
Trevena Announces Reverse Stock Split |
|
06/20/2024 |
News Article |
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models |
|
12/04/2023 |
News Article |
Trevena Awarded OLINVYK Agreement with Premier, Inc. |